SLDB
Solid Biosciences Inc
NASDAQ · Biotechnology
$6.52
+0.29 (+4.65%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 294.33M | 265.12M | 296.42M |
| Net Income | 32.12M | 33.11M | 29.81M |
| EPS | — | — | — |
| Profit Margin | 10.9% | 12.5% | 10.1% |
| Rev Growth | +16.9% | -8.0% | -9.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 84.11M | 71.30M | 90.12M |
| Total Equity | 250.64M | 261.66M | 250.70M |
| D/E Ratio | 0.34 | 0.27 | 0.36 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 56.98M | 46.74M | 49.34M |
| Free Cash Flow | 40.15M | 38.44M | 35.75M |